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Abstract: Animal models fed low calcium diets demonstrate a negative calcium balance 
and  gross  bone  loss  while  the  combination  of  calcium  deficiency  and  oophorectomy 
enhances overall bone loss. Following oophorectomy the dietary calcium intake required to 
remain  in  balance  increases  some  5  fold,  estimated  to  be  approximately  1.3%  dietary 
calcium. In the context of vitamin D and dietary calcium depletion, osteomalacia occurs 
only  when  low  dietary  calcium  levels  are  combined  with  low  vitamin  D  levels  and 
osteoporosis occurs with either a low level of dietary calcium with adequate vitamin D 
status or when vitamin D status is low in the presence of adequate dietary calcium intake. 
Maximum bone architecture and strength is only achieved when an adequate vitamin D 
status is combined with sufficient dietary calcium to achieve a positive calcium balance. 
This anabolic effect occurs without a change to intestinal calcium absorption, suggesting 
dietary calcium and vitamin D have activities in addition to promoting a positive calcium 
balance.  Each  of  the  major  bone  cell  types,  osteoblasts,  osteoclasts  and  osteocytes  are 
capable of metabolizing 25 hydroxyvitamin D (25D) to 1,25 dihydroxyvitamin D (1,25D) 
to elicit biological activities including reduction of bone resorption by osteoclasts and to 
enhance  maturation  and  mineralization  by  osteoblasts  and  osteocytes.  Each  of  these 
activities is consistent with the actions of adequate circulating levels of 25D observed in vivo. 
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1. Introduction  
Experimentation on a variety of animal models for over 80 years has clearly demonstrated that low 
dietary  calcium,  particularly  in  adult  animals,  produces  osteoporosis,  defined  as  a low quantity of 
normally mineralized bone. In contrast, vitamin D deficiency, especially in young animals, produces 
osteomalacia,  defined  as  a  defect  in  bone  mineralization.  Both  osteoporosis  and  osteomalacia 
compromise the strength of bone and in humans increase the risk of fracture. They can occur in concert 
although they arise by distinct etiologies, a fact which has not always been recognized, particularly 
with regard to interpretation of the effects of vitamin D deficiency on bone structure. Severely vitamin D 
deficient animals are hypocalcemic, hypophosphatemic and demonstrate secondary hyperparathyroidism 
resulting in osteomalacia. Dietary studies with genetically modified mouse models in which vitamin D 
activity has been ablated indicate that osteomalacia can be resolved with a diet high in calcium and 
phosphate,  which  normalizes  the  plasma  calcium  and  phosphate  levels.  Thus  currently  the  major 
question with regard to vitamin D activity and bone tissue is whether vitamin D can act directly on 
bone cells to modulate skeletal health. 
2. Dietary Calcium Deficiency 
Studies from the early decades of the 20th Century identified that various animal models fed a diet 
low in calcium demonstrated a negative calcium balance and gross bone loss [1]. Bauer and colleagues 
studied the effects of low calcium diets on cats by visual inspection of longitudinal sections of the 
humerus [1]. They found that significant bone loss was evident from the trabecular bone compartment 
in contrast to cortical bone and concluded that the trabecular compartment of bone tissue was the 
metabolically  most  active  compartment  of  the  skeleton.  Using  the  technique  of  bone  ash  weight 
Hodgkinson  and  colleagues  could  only  detect  significant  bone  loss  when  calcium  deficiency  was 
combined  with  estrogen  deficiency  following  oophorectomy  [2].  However  with  the  availability  of  
2-dimensional  bone  histomorphometry,  bone  losses,  quantified  as  a  reduction  of  trabecular  bone 
volume as a fraction of total volume (BV/TV) in the trabecular compartment and a reduction of cortical 
bone volume in the cortical compartment, were detected following dietary calcium deprivation while 
with  oophorectomy  bone  loss  was  only  detectable  in  the  trabecular  bone  compartment  [3].  Their 
studies identified that bone loss with estrogen deficiency was the result of perforation and dissolution 
of  individual  trabeculae  and  the  conversion  of  trabecular  plates  into  rods  as  a  result  of a marked 
increase  in  osteoclastic  bone  resorption.  They  also  confirmed  that  the  combination  of  calcium 
deficiency and oophorectomy enhanced overall bone loss.  
Shen  and  colleagues  noted  difficulties  with  conducting  studies  on  rat  models  including  the 
uncertainty  of  the  calcium  requirement  for  mature  rats  and  therefore  difficulty  estimating  what 
constituted high and low dietary contents. As well the impact of growth possibly confounded the use of 
rodents in such studies. Careful calcium balance data were later published indicating that mature ovary-Nutrients 2010, 2  
 
 
1028
intact, 6 month-old Sprague-Dawley female rats required 0.2% dietary calcium to remain in balance, 
that is a 0.2% calcium intake was sufficient to balance for losses of calcium in the urine and faeces [4]. 
Following oophorectomy the dietary calcium intake to remain in balance increases to over 1% with an 
estimate of approximately 1.3% dietary calcium required to remain in balance [4]. These important 
data clearly identified that diets below 0.2% placed ovary-intact, adult female rats in a negative calcium 
balance, with losses of calcium in the urine and faeces being greater than the dietary intake of calcium 
and therefore under these conditions it is necessary to mobilise calcium from the skeleton to maintain 
plasma  calcium  homeostasis.  Baldock  and  colleagues  carefully  characterized  the  femoral  growth 
characteristics of female Sprague-Dawley rats reporting that growth was markedly slowed between 5 
and 7 months of age and was undetectable after 12 months of age despite the presence of a growth 
plate until at least 18 months of age [5]. These data have improved the adult rat model for the study of 
hormonal and dietary factors on bone mineral homeostasis. However dietary calcium requirements for 
rats during growth, pregnancy or lactation remain to be carefully quantified and are likely to be greater 
than for adult animals. 
3. The Interaction between Estrogen and Dietary Calcium Deficiencies  
In  the  adult  rat,  estrogen  deficiency  as  a  result  of  oophorectomy,  initially  stimulates 
osteoclastogenesis and bone resorption, which is detectable at 6 days post operation. This is followed 
by an increase in bone formation markers at 9 days with trabecular bone loss not being detectable 
before 15 days post oophorectomy [6]. This increase in bone cell activity is likely to be the sum of the 
effects resulting from the removal of the suppressive effect that estrogen exerts on bone cells to reduce 
expression of RANKL and other cytokines which stimulate osteoclastogenesis [7] and the requirements 
to maintain blood calcium homeostasis in the face of a negative calcium balance. The contribution of 
each of these factors is yet to be quantified. 
Estrogen deficiency in the adult rat model fed a 0.8–1% calcium diet stimulates trabecular bone loss 
in the distal femoral metaphysis and diaphysis regions but not in the epiphysis [8,9]. However when 
dietary calcium is reduced to 0.2% bone loss following oophorectomy is detectable in each of these 
three regions [10]. Extra bone loss occurs in the metaphysis when diet calcium is further reduced to 
0.04% in ovary-intact rats but no further loss occurs in the epiphysis (Figure 1).  
Thus  despite  highly  similar  architecture  amongst  these  three  trabecular  bone  regions  there  is  a 
differentiation  with  regard  to response to increased osteoclastogenesis and rate of bone loss when 
dietary calcium is limiting [8]. Trabecular bone in the epiphysial region, which is encased in a thin 
cortex, experiences considerably higher mechanical forces than other regions (Figure 2). In contrast 
trabeculae in the metaphysis and particularly the diaphysis are encased in thicker cortices and therefore 
experience significantly reduced mechanical forces. These data strongly suggest that during estrogen 
depletion regions of bone which experience greater mechanical forces are preferentially maintained 
over  the  regions  of  bone  which  experience  a  reduced  mechanical  load.  This  occurs  despite  the 
increased bone cell activities due to the negative calcium balance. However, over an extended duration 
of estrogen depletion or further reduction in dietary calcium intake, bone resorption in these regions of 
high mechanical load occur, presumably following the resorption of bone from the readily accessible 
stores (Lee MC, O’Loughlin PD, Anderson PH, unpublished data). Nutrients 2010, 2  
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Figure  1.  Trabecular  bone  volume  (BV/TV)  in  the  distal  femora  from  10-month  old 
Sprague-Dawley  rats  following  4  months  of  dietary  calcium  feeding  and  3  months  
post-operation: (A) Metaphyseal region; (B) Epiphyseal region. White bars: ovary-intact, 
sham operated; Grey bars: oophorectomized. 
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Figure  2.  Scanning  electron  micrographs  of  distal  femora  from  11-month  old  
Sprague-Dawley  female  rats  fed  0.8%  diet  calcium  at  150  days  post-operation:  
(A) Ovary-intact, sham operation; (B) Oophorectomized. In the Diaphyseal and Metaphyseal 
region bone loss is evident following oophorectomy which is absent in the epiphysis. 
 
The importance to bone health of maintaining a positive calcium balance in the presence of high 
bone turnover such as with estrogen deficiency is demonstrated with very interesting preliminary data 
we  have  recently  obtained.  Adult  female  Sprague-Dawley  rats,  fed  0.4%  calcium,  were 
oophorectomized at 3 months of age, losing bone over a further 3 months. These animals were then 
placed on diets varying in calcium from 0.4% to 1.6%, the latter diet providing sufficient calcium for 
estrogen-deficient rats to attain a positive calcium balance. At 9 months of age, after a further 3 months 
on these diets trabecular bone volume had returned to the levels of ovary-intact animals maintained on 
diets providing a positive calcium balance [11]. Most interesting from this study was the finding that 
the  oophorectomized  animals  fed  the  highest  diet  calcium  demonstrated  the  lowest  activation 
frequency for bone turnover, the highest mean wall thickness and the longest formation period. These 
data suggest that a dietary calcium level sufficient to attain a positive calcium balance can modulate Nutrients 2010, 2  
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bone cell activity to reduce bone turnover with an extension of the time during which osteoblasts form 
new bone within the basic multicellular unit during each bone turnover event. 
4. The Interaction between Vitamin D and Dietary Calcium Deficiencies 
It  has  long  been  established  that  marked  vitamin  D  deficiency  results  in  osteomalacia,  a  bone 
mineralization defect associated with hypocalcemia, hypophosphataemia and hyperparathyroidism [12]. 
However the relationship between low vitamin D status and osteoporosis, a condition with normal 
mineralization but low bone volume, has also been claimed to result from depleted vitamin D levels. A 
report from the 1970’s that patients with hip fractures have a depleted vitamin D status [13] was 
confirmed at a temperate latitude [14] where a mean serum 25D value of 40 nmol/L for hip fracture 
patients was found. There is strong evidence of the association between a low vitamin D status and low 
bone mineral density [15] however the nature of the bone defect has not been clearly defined as hip 
fractures and low bone density can result from either osteoporosis or osteomalacia.  
Variation  of  dietary  vitamin  D  and  calcium  levels  fed  to  adult  female  rats  has  provided  very 
interesting data as to the differential effects of deficient levels of these nutrients. Rats were allocated to 
either vitamin D deficient or replete diets and then further allocated to 0.1% or 1% calcium diets for 
3 months. Rats fed the vitamin D deplete diet achieved mean serum 25-hydroxyvitamin D (25D) levels 
of 14 nmol/L while animals fed vitamin D replete diets achieved 25D levels of 97 to 135 nmol/L [16]. 
Osteoid maturation time (OMT) was significantly higher (12.6 days) in the vitamin D deplete/0.1% 
calcium  group,  a  result  which  is  diagnostic  for  osteomalacia.  In  the  remaining  groups  OMT  was 
approximately 6 days therefore excluding osteomalacia. However metaphyseal trabecular bone volume 
and cortical width were reduced in both vitamin D replete/0.1% calcium and vitamin D deplete/1% 
calcium groups compared with rats fed the vitamin D replete/1% calcium (Anderson PH, Iida S, Morris 
HA, unpublished data, Figure 3). These data indicate that in the context of vitamin D and dietary 
calcium  depletion,  osteomalacia  occurs  only  when  both  vitamin  D  and  dietary  calcium  levels  are 
markedly reduced and osteoporosis occurs with either a low calcium diet alone or when vitamin D 
status is low and dietary calcium is adequate.  
A major controversy in this field is the suggestion that vitamin D receptor or vitamin D activity 
within  bone  cells  is  redundant  for  normal  bone  health.  The  controversy  has  arisen  because 
osteomalacia, whether as a result of nutritional deficiency of vitamin D or genetic ablation of vitamin 
D activity can be resolved by nutritional supplementation of calcium and phosphate alone [17,18]. 
Statements  have  been  made  that  such  “rescue”  diets  return  the  bone  structure  to  “normal”  [18]. 
However these studies particularly with genetically modified mice have often been completed at an age 
of  less  than  12  weeks  when  growth  continues  at  a  relatively  high  rate.  One  study  
with  genetically  modified  mice,  in  which  either  the  vitamin  D  receptor  (Vdr)  gene  or  the  
25-hydroxyvitamin D-1α-hydroxylase (Cyp27b1) genes were ablated, was continued until mice were 
16 weeks of age [19]. They found that while the genetically modified mice fed the rescue diet had 
resolved the osteomalacia, the femoral metaphyseal trabecular bone volume was only approximately 
50% of that in the age- and sex-matched wild type mice. These data suggest that in addition to its 
action to stimulate intestinal calcium absorption vitamin D activity is also required for the normal Nutrients 2010, 2  
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function  of  cells  involved  in  bone  turnover.  New  models  of  cell-specific  ablation  of  the  Vdr  are 
required to elucidate the relative roles of vitamin D activity within the bone micro-environment. 
Figure 3. Longitudinal sections (Von Kossa stained) of 9-month old Sprague-Dawley rat 
distal femora following 3 months feeding either (A) 1% calcium/20 IU vitamin D3/day;  
(B)  1%  calcium/0  IU  vitamin  D3/day;  (C)  0.1%  calcium/20  IU  vitamin  D3/day;  
(D) 0.1% calcium /0 IU vitamin D3/day. Highly trabecularized bone with osteomalacia (D) 
is evident in contrast to reduced trabecular bone volume (B &C) compared to (A). 
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As discussed above increased risk of hip fracture in the elderly is associated with mean serum 25D 
values  of  approximately  40  nmol/L  [12].  Furthermore  clinical  studies  indicate  that  the  risk  of  
non-vertebral fractures including the hip does not reduce until serum 25D levels of 80 nmol/L or 
greater are achieved [20]. However the effects on bone cell activities of such levels of vitamin D are 
unknown. Rodent studies have been most useful for the investigation of this issue. Young adult rats  
(3 months of age) fed a 0.4% calcium, vitamin D deficient diet achieved a mean serum 25D level of 
12 nmol/L with an OMT indicative of osteomalacia [21]. When serum 25D was raised to 22 nmol/L 
osteomalacia  was  resolved  while  osteoporosis  was  evident  in  the  groups  with  serum  25D  levels 
between 22 and 80 nmo/L. This loss of trabecular bone volume was due to increased bone resorption as 
a  result  of  increased  expression  of  the  RankL  gene  in  bone  and  increased  osteoclastogenesis.  No 
relationship was found between bone volume and either serum 1,25D or parathyroid hormone [21]. 
Further  studies  have  been  conducted  with  15  month  old  rats  comparing  the  effects  of  varying 
vitamin D status on 0.1% or 1% calcium diets (Lee MC, Anderson PH, O’Loughlin PD unpublished 
results).  The  positive  relationship  between  trabecular  bone  volume  and  serum  25D  levels  was 
confirmed and extended to a similar relationship between cortical bone volume and 25D levels with a 
maximum cortical bone volume being achieved at 25D levels of 100 nmol/L or greater. Furthermore 
our studies indicate that increasing 25D levels to greater than 80 nmol/L was effective in increasing 
cortical  bone  volume  only  in  animals  achieving  a  positive  calcium  balance.  Consistent  with  the 
increased cortical bone volume, increased bone strength was only achieved in animals fed 1% calcium 
and serum 25D levels greater than 80 nmo/L. Therefore for rodent models osteomalacia occurs when Nutrients 2010, 2  
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fed calcium diets at or below the level required to achieve a positive calcium balance and serum 25D 
levels are below 20 nmol/L. When 25D levels are between 20 and 80 nmol/L bone loss occurs at both 
the trabecular and cortical compartments. Maximum bone architecture and strength is only achieved 
when an adequate vitamin D status is combined with sufficient dietary calcium to achieve a positive 
calcium balance. 
As discussed above these data indicate that the major circulating vitamin D metabolite associated 
with  increased  bone  structure  and  strength  is  the  pro-hormone  25D  and  not  the  active  metabolite 
1,25D. To investigate whether normal levels of serum 1,25D can act in the same manner as serum 25D 
to suppress osteoclastogenesis and bone resorption, adult female rats with 25D levels at approximately 
20 nmol/L were infused with 1,25D. In contrast to the suppression of the expression of the RankL gene 
in bone by increasing circulating 25D, 1,25D infusion increased the expression of the RankL gene in 
bone  with  no  detectable  suppression  of  osteoclasts  over  the  14  days  of  the  infusion  [Sawyer  R, 
Anderson  PH,  Morris  HA  unpublished  results].  Thus  experimental  data  strongly  indicate  that  the 
circulating levels of the pro-hormone 25D are necessary to optimise bone architecture rather than the 
active metabolite 1,25D. The question as to what is the biological activity of 25D in bone cells is of 
considerable interest. 
5. Endogenous Metabolism of Vitamin D within Bone Cells 
Each of the major bone cells, osteoblasts, osteoclasts and osteocytes are capable of metabolizing 
25D  to  1,25D  to  elicit  biological  activities.  Human  and  rodent  osteoblasts  strongly  express  the  
25-hydroxyvitamin D-1,α-hyroxylase (CYP27B1) enzyme which is essential to convert 25D to 1,25D 
and to increase expression of key genes associated with maturation and mineralization [22]. 25D in the 
osteoblast  culture  media  reduces  cell  proliferation  and  stimulates  osteoblast  maturation  and 
mineralization  in  vitro.  More  recently,  it  has  been  demonstrated  that  Cyp27b1  expression  in  pre-
osteoclast cells is also necessary for 25D to increase osteoclastogenesis [23]. Interestingly osteoclasts 
formed  in  the  presence  of  25D  demonstrated  reduced  resorbing  activity  than  cells  matured  in  the 
absence of vitamin D metabolites or cells in which the Vdr gene has been ablated. Osteocytes also 
express the Cyp27b1 gene and mRNA levels increase with differentiation and are associated with the 
acquisition of mature osteocyte genes including Mepe (Matrix extracellular PhosphoglycoprotEin), 
Dmp1 (Dentin matrix protein 1), Phex (Phosphate-regulating gene with Homologies to Endopeptidase 
on the X chromosome) (Atkins GJ, unpublished data) and Fgf23 (fibroblast growth factor 23) [24]. 
Thus in vitro data provide strong evidence that the pro-hormone 25D is capable of metabolism by bone 
cells to the active hormone 1,25D to elicit various activities including the reduction of bone resorption 
by osteoclasts and to enhance maturation and mineralization by osteoblasts and osteocytes. Each of 
these activities is consistent with the actions of adequate circulating levels of 25D observed in vivo. 
As discussed above the anabolic effects of circulating 25D on the skeleton are dependent on a 
dietary calcium intake sufficient to ensure a positive calcium balance that is a dietary calcium intake 
which provides a greater amount of calcium than is excreted from the body via the urine and faeces. 
The question arising from such findings is whether calcium exerts any biological activities within the 
skeletal  system  rather  than  simply  providing  a  raw  material,  in  conjunction  with  phosphate,  for 
mineralization. In vitro studies indicate that the addition of calcium to culture media enhances the Nutrients 2010, 2  
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ability of osteoblast-like cells to mineralize in vitro (Yang D, Atkins GJ, Morris HA unpublished 
results). Interestingly a recent report describes that when rats are fed a dietary calcium level sufficient 
to ensure a positive calcium balance, the levels of Cyp27b1 mRNA are 3-fold higher in bone tissue 
compared with animals fed a low calcium diet [16]. Messenger RNA levels for Cyp24, which codes for 
the vitamin D catabolic enzyme 25-hydroxyvitamin D 24-hydroxylase and is highly regulated by 1,25D 
were also elevated in bone from these animals suggesting that 1,25D levels are also higher in the bone 
tissue. Thus, a contributing effect of adequate dietary calcium intake to their positive effects on bone 
mineral homeostasis may be, at least in part, through increasing the synthesis of 1,25D within bone 
tissue. 
6. Conclusions  
Studies in animals have identified that feeding low levels of dietary calcium produces a negative 
calcium  balance  and  gross  bone  loss.  The  calcium  requirement  in  the  estrogen  deficient  state  is 
markedly increased and therefore the combination of calcium deficiency and oophorectomy enhances 
overall bone loss. In the context of vitamin D and dietary calcium depletion, osteomalacia occurs only 
when both vitamin D and dietary calcium levels are reduced and osteoporosis occurs with either a low 
calcium diet in the presence of adequate vitamin D or when vitamin D status is low in the presence of 
adequate dietary calcium. Maximum bone architecture and strength is only achieved when an adequate 
vitamin D status is combined with sufficient dietary calcium to achieve a positive calcium balance. 
Each of the major bone cells, osteoblasts, osteoclasts and osteocytes are capable of metabolizing 25D 
to 1,25D to elicit biological activities including reduction of bone resorption by osteoclasts and to 
enhance maturation and mineralization by osteoblasts and osteocytes. Thus optimal bone health is only 
achieved when the vitamin D status is improved thus providing adequate levels of the circulating  
pro-hormone 25D for local metabolism by bone cells into the active hormone 1,25D. Each of these 
bone cell activities is consistent with the actions of adequate circulating levels of 25D observed in vivo 
and with clinical outcomes from vitamin D and calcium dietary supplementation. 
Valuable data have been derived from animal experimentation on the physiological responses of 
bone mineral homeostasis to variations in dietary calcium intake and vitamin D status in both the 
context of estrogen sufficiency and deficiency. Such data provide support for clinical studies, often 
derived from epidemiological or case control study formats, indicating that nutritional deficiencies of 
calcium and vitamin D, especially in postmenopausal women, produce adverse bone health outcomes 
and  increase  the  risk  of  osteoporotic  fractures.  Animal  studies  provide  research  models  for 
investigating  the  mechanisms  by  which  such  adverse  outcomes  may  arise  allowing  the  combined 
investigation of bone architecture, bone cell activities and molecular changes in response to nutritional 
manipulation. Knowledge of the molecular and cellular basis is essential for defining the nutritional 
levels required for optimal health outcomes, for acceptance by the clinical community of the essential 
requirements for calcium and vitamin D nutrition and for the development of public health policies 
aimed at osteoporosis prevention.  Nutrients 2010, 2  
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